• Pharmaceutical Laboratory for Sterile API Production

    September 30, 2011


    We have been Audited and Approved by Spanish Health Authorities (AEMPS), for the Manufacture and Release of Sterile Peptide Ingredients, after 3 days audit (28-30 September 2011).

    At the same time we have received the renewal for the Authorization as Pharmaceutical Laboratory for Quality Control and also for the Production of GMP Peptides.

  • ProRetina Therapeutics

    May 20, 2011


    ProRetina, spin-off of Biological Investigation Center (CSIC), GP Pharm Biopharmaceutical and BCN Peptides, fine chemicals division of Lipotec Group, have agreed to form a consortium to deal with the development of formulations that allow drugs to vehicular to the retina.

    The union aims to improve quality of patient’s life through the treatment of eye diseases such as retinitis pigmentosa and other retinal dystrophies. Download full Press Release

  • European Consortium for the Early Treatment of Diabetic Retinopathy

    April 28, 2011


    BCN Peptides is one of the Key Partners of the European Consortium for the Early Treatment of Diabetic Retinopathy. The Project has been positively evaluated by the European Commission and have proceed to negotiations for a Grant Agreement.